V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016323 | 160016327 | 1.62 | 14.4 | Palliative (P) | 2019-08-24 | 2019-08-27 | Doxorubicin + Ifosfamide | 02 | null | ETOPOSIDE | 101402071 |
| 160016340 | 160016328 | 1.82 | 86.5 | null | 2020-08-03 | 2020-08-21 | Cyclophosphamide oral | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100530002 |
| 160016341 | 160016329 | 1.45 | 86 | null | 2021-08-03 | 2021-09-09 | Trial Unspecified | 02 | null | OLARATUMAB | 101869418 |
| 160016342 | 160016330 | 0 | 70 | Palliative (P) | 2019-04-29 | 2019-09-09 | EW EuroEwing 2012 Arm B IE | 02 | N | TRIAL | 100428007 |
| 160016345 | 160016331 | 1.7 | 58.6 | Curative (C) | 2019-12-22 | 2020-03-23 | VAC | 02 | N | GEMCITABINE | 100784492 |
| 160016347 | 160016332 | 0 | 99 | Curative (C) | 2017-06-12 | 2017-06-16 | Niraparib | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101595710 |
| 160016348 | 160016333 | 1.69 | 63.25 | Palliative (P) | null | 2018-02-11 | GEMCITABINE | 02 | Y | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 100954658 |
| 160016356 | 160016334 | 1.65 | 84.7 | null | 2017-10-18 | 2017-10-22 | Etoposide + Ifosfamide (5 days) | 02 | null | NIRAPARIB | 100530545 |
| 160016357 | 160016335 | 1.82 | 88.5 | Curative (C) | 2021-05-10 | 2021-05-12 | Rucaparib | 02 | N | EW EUROEWING 2012 ARM B VC | 101033314 |
| 160016361 | 160016336 | 1.62 | 78.2 | Palliative (P) | 2020-10-19 | 2020-10-20 | FLUOROURACIL + IRINOTECAN | 02 | N | IFOSFAMIDE | 101091128 |
| 160016362 | 160016337 | 0 | 60.5 | null | 2018-11-03 | 2018-11-03 | VAC | 02 | null | CONFIRM TRIAL | 101279426 |
| 160016366 | 160016338 | 1.68 | 22 | Palliative (P) | 2018-03-23 | 2018-06-29 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | IMATINIB | 101311932 |
| 160016368 | 160016339 | 1.84 | 89.5 | null | null | 2018-03-12 | Olaparib | 2 | null | STS RHABDO RMS 2005 VIN CYCLO | 101578769 |
| 160016371 | 160016340 | 1.63 | 17.8 | null | 2018-04-30 | 2018-05-05 | EW EuroEwing 2012 Arm B IE | 01 | null | ETOPOSIDE + IFOSFAMIDE + METHOTREXATE | 101092422 |
| 160016374 | 160016341 | null | null | Palliative (P) | 2019-01-03 | 2019-01-03 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | NB HRNBL-1 BUMEL MAT | 101130449 |
| 160016388 | 160016342 | 1.74 | 59.6 | Neo-adjuvant (N) | 2018-03-01 | 2018-03-30 | NB HRNBL-1 COJEC Ind COURSE A | 02 | Y | NOT MATCHED | 101042391 |
| 160016389 | 160016343 | 1.59 | 62 | Palliative (P) | 2017-02-19 | 2017-02-19 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | PEMETREXED | 100501408 |
| 160016399 | 160016344 | 1.63 | 107.2 | Curative (C) | 2020-12-17 | 2020-12-17 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100864276 |
| 160016402 | 160016345 | 1.69 | 81.2 | null | 2019-09-18 | 2019-09-19 | NB HRNBL-1 Isotretinoin | 02 | null | ERIBULIN | 100789613 |
| 160016403 | 160016346 | 1.61 | 67.8 | Palliative (P) | 2016-07-09 | 2016-10-18 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | IFOSFAMIDE | 100364118 |
| 160016405 | 160016347 | 1.64 | 70.6 | Curative (C) | 2018-12-12 | 2019-05-16 | Rucaparib | 02 | N | CABOZANTINIB | 101466526 |
| 160016409 | 160016348 | 1.09 | 58.2 | null | 2019-01-03 | 2019-01-17 | CARBOPLATIN + VINORELBINE | null | null | NB HRNBL-1 ISOTRETINOIN | 101579720 |
| 160016420 | 160016349 | 1.72 | 78.5 | Curative (C) | 2019-08-10 | 2019-08-19 | IVA | 02 | N | DACARBAZINE + GEMCITABINE | 101362526 |
| 160016428 | 160016350 | 1.87 | 116 | Palliative (P) | 2019-12-29 | 2020-01-05 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | RMS 2005 TRIAL | 101731054 |
| 160016429 | 160016351 | 1.6 | 50 | Curative (C) | 2017-06-03 | 2017-06-13 | GEMCITABINE | N | Y | STS NON-RHABDO EPSSG 2005 IVA | 100736808 |
| 160016432 | 160016352 | 1.78 | 51.1 | null | 2018-11-30 | 2018-12-11 | Cyclophosphamide oral | 2 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 101507553 |
| 160016440 | 160016353 | 1.77 | 143 | null | 2016-11-07 | 2016-12-22 | PEMBROLIZUMAB | 02 | null | PEMBROLIZUMAB | 100907107 |
| 160016444 | 160016355 | 1.58 | 50.9 | 03 | 2020-01-27 | 2020-02-13 | Pemetrexed | 01 | N | NB BEACON TEMOZOLOMIDE AND TOPOTECAN | 100920605 |
| 160016447 | 160016356 | 1.45 | 66.7 | Palliative (P) | 2018-01-03 | 2019-03-22 | Cyclophosphamide + Vincristine | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101003237 |
| 160016454 | 160016357 | null | 65.8 | 03 | 2019-05-14 | 2019-06-01 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 101601332 |
| 160016462 | 160016358 | 1.86 | 11.2 | Palliative (P) | 2017-02-26 | 2017-04-08 | null | 02 | null | BORTEZOMIB + DARATUMUMAB | 101660087 |
| 160016467 | 160016359 | 0 | 61.4 | null | 2018-08-01 | 2018-08-02 | VAI (Ifos 3g/m2) | 02 | null | STS RHABDOMYOSARCOMA RELAPSE IRINOTECAN/ TEMOZOLOMIDE/ VINCRISTINE | 100434212 |
| 160016468 | 160016360 | 1.43 | 94.15 | Curative (C) | null | 2018-02-18 | Cyclophosphamide + Vincristine | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101166820 |
| 160016477 | 160016361 | 1.62 | 15.1 | Curative (C) | 2019-06-07 | 2019-06-15 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101786150 |
| 160016479 | 160016362 | 1.81 | 7.8 | null | 2019-07-26 | 2019-07-27 | IVA | Y | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100294636 |
| 160016488 | 160016363 | 1 | 73.75 | null | 2018-06-02 | 2018-06-04 | Olaparib | 02 | null | IFOSFAMIDE | 100949605 |
| 160016489 | 160016364 | 1.6 | null | Neo-adjuvant (N) | 2016-11-06 | 2017-05-29 | CYCLOPHOSPHAMIDE | 02 | N | TRIAL | 100100749 |
| 160016492 | 160016365 | 0 | 59.7 | Curative (C) | null | null | CAPECITABINE + TEMOZOLOMIDE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101692118 |
| 160016496 | 160016366 | 1.64 | 109 | Neo-adjuvant (N) | 2018-02-06 | 2018-04-12 | ETOPOSIDE + IFOSFAMIDE | 02 | N | EW REL REECUR GEMCITABINE/DOCETAXEL | 100199683 |
| 160016502 | 160016367 | 0 | 21.8 | Palliative (P) | 2021-09-29 | 2021-09-29 | Rituximab | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101772014 |
| 160016503 | 160016368 | 1.9 | 56.4 | null | 2017-03-07 | 2017-03-07 | Bortezomib (weekly) | 02 | null | GEMCITABINE | 101759217 |
| 160016510 | 160016369 | 1.45 | 16.5 | Palliative (P) | 2017-10-16 | 2018-01-20 | Cisplatin + Gemcitabine (D 1 & 8) | Y | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101787090 |
| 160016516 | 160016370 | 0.6 | 70 | Palliative (P) | 2016-02-24 | 2016-03-16 | ETOP 13-18 BEAT-meso Trial | 02 | N | RITUXIMAB | 100085188 |
| 160016526 | 160016372 | 1.64 | 74.3 | null | null | null | CYCLOPHOSPHAMIDE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101319145 |
| 160016528 | 160016373 | 1.6 | 11.6 | null | 2019-12-13 | 2020-01-15 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 101194974 |
| 160016530 | 160016374 | 1.56 | 17.6 | null | 2016-06-13 | 2018-06-13 | CISPLATIN + GEMCITABINE | N | null | STS RHABDO RMS 2005 VIN CYCLO | 101066328 |
| 160016540 | 160016375 | null | 17 | Palliative (P) | 2021-03-24 | 2021-04-22 | Niraparib | 02 | N | IVA | 101003034 |
| 160016543 | 160016376 | 1.63 | 98.5 | null | 2019-01-28 | 2019-02-16 | Capecitabine + Oxaliplatin 21day | 02 | null | TRIAL | 100687076 |
| 160016547 | 160016377 | 0 | 105.8 | Palliative (P) | 2018-08-31 | 2018-09-16 | Cyclophosphamide + Vincristine | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 100387025 |
| 160016557 | 160016378 | 1.78 | 63.7 | null | 2019-03-29 | 2019-11-24 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + DOXORUBICIN + VINCRISTINE | 02 | null | DACTINOMYCIN + CYCLO + VINCRISTINE | 100069644 |